- Home
- ANGO vs DSGN Comparison
ANGO vs DSGN Comparison
Compare ANGO & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- DSGN
- Stock Information
- Founded
- ANGO 1988
- DSGN 2017
- Country
- ANGO United States
- DSGN United States
- Employees
- ANGO N/A
- DSGN N/A
- Industry
- ANGO Medical/Dental Instruments
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- DSGN Health Care
- Exchange
- ANGO Nasdaq
- DSGN Nasdaq
- Market Cap
- ANGO 400.8M
- DSGN 418.1M
- IPO Year
- ANGO 2004
- DSGN 2021
- Fundamental
- Price
- ANGO $12.45
- DSGN $9.22
- Analyst Decision
- ANGO Strong Buy
- DSGN Buy
- Analyst Count
- ANGO 3
- DSGN 1
- Target Price
- ANGO $19.33
- DSGN $13.00
- AVG Volume (30 Days)
- ANGO 466.5K
- DSGN 457.9K
- Earning Date
- ANGO 01-07-2026
- DSGN 11-05-2025
- Dividend Yield
- ANGO N/A
- DSGN N/A
- EPS Growth
- ANGO N/A
- DSGN N/A
- EPS
- ANGO N/A
- DSGN N/A
- Revenue
- ANGO $300,718,000.00
- DSGN N/A
- Revenue This Year
- ANGO $8.18
- DSGN N/A
- Revenue Next Year
- ANGO $5.15
- DSGN N/A
- P/E Ratio
- ANGO N/A
- DSGN N/A
- Revenue Growth
- ANGO 2.73
- DSGN N/A
- 52 Week Low
- ANGO $6.91
- DSGN $2.60
- 52 Week High
- ANGO $13.50
- DSGN $9.85
- Technical
- Relative Strength Index (RSI)
- ANGO 58.66
- DSGN 71.64
- Support Level
- ANGO $11.35
- DSGN $8.21
- Resistance Level
- ANGO $12.50
- DSGN $9.85
- Average True Range (ATR)
- ANGO 0.44
- DSGN 0.68
- MACD
- ANGO 0.00
- DSGN 0.20
- Stochastic Oscillator
- ANGO 74.52
- DSGN 82.97
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.